Inventiva (NASDAQ:IVA) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Inventiva (NASDAQ:IVA) announced its quarterly earnings results on Monday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08), reports. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $2.88 million.

Here are the key takeaways from Inventiva’s conference call:

• NATiV3 Phase III remains on track for top-line MASH results in Q4 2026 after the final patient completed the 72-week visit; the main cohort includes 1,009 patients with biopsy-confirmed F2/F3 MASH.
• If results are positive, Inventiva plans to pursue an FDA NDA filing in the first half of 2027 and a potential U.S. commercial launch in 2028, while also preparing a confirmatory outcomes trial in advanced compensated liver disease.
• Management highlighted Phase IIb results showing placebo-adjusted improvements in fibrosis, MASH resolution and the composite endpoint, supporting its view that once-daily oral lanifibranor could address both hepatic and metabolic drivers of disease.
• The company expects to evaluate whether both doses should be commercialized, depending on Phase III efficacy and tolerability; it has not disclosed the scope of the Q4 data release or subgroup results for patients using GLP-1 or SGLT2 therapies.
• Lanifibranor’s known PPAR-gamma-related effects include weight gain, edema and hemoglobin decline, although management characterized them as generally mild to moderate and potentially manageable with therapies such as SGLT2 inhibitors.
• Following its June financing actions, Inventiva reported €233.9 million in cash and short-term deposits and a cash runway through Q2 2027, potentially extending to early 2028 if additional financing tranches and warrants are realized.

Inventiva Stock Up 4.7%

Shares of IVA stock opened at $3.53 on Tuesday. The stock has a 50-day moving average of $4.41 and a 200-day moving average of $4.73. Inventiva has a one year low of $3.11 and a one year high of $7.98.

Key Headlines Impacting Inventiva

Here are the key news stories impacting Inventiva this week:

• Positive Sentiment: Inventiva reported a narrower first-half loss, reflecting lower expenses and improved cost control. The company also maintained its cash runway outlook through the end of the second quarter of 2027, reducing near-term financing concerns. Inventiva H1 Loss Plunges; MASH Drug Readout Expected This Quarter
• Positive Sentiment: A clinical readout for lanifibranor, Inventiva’s lead treatment candidate for metabolic dysfunction-associated steatohepatitis (MASH), is expected this quarter. The data could be a significant catalyst because the company remains primarily valued on the potential of its pipeline rather than current revenue. Inventiva Reports Unaudited 2026 First-Half Financial Results
• Neutral Sentiment: Management’s earnings materials and conference call focused on the company’s development programs, financial position and upcoming MASH data, leaving investors cautious ahead of the clinical update. Inventiva Q2 2026 Earnings Call Transcript
• Negative Sentiment: Inventiva’s quarterly results missed analyst expectations: adjusted loss was $0.28 per share versus the $0.20 consensus loss, while revenue of approximately $0.02 million was far below the $2.88 million estimate. The revenue shortfall highlights the company’s limited commercial base and increases its dependence on clinical success and future financing. Inventiva Quarterly Earnings Report

Analysts Set New Price Targets

A number of brokerages have commented on IVA. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Piper Sandler restated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Finally, Guggenheim lifted their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $15.75.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.